» Articles » PMID: 18064039

Granzyme B-induced Cell Death Exerted by Ex Vivo CTL: Discriminating Requirements for Cell Death and Some of Its Signs

Overview
Specialty Cell Biology
Date 2007 Dec 8
PMID 18064039
Citations 44
Authors
Affiliations
Soon will be listed here.
Abstract

Granzyme B (gzmB) of cytotoxic T lymphocytes (CTL) is essential for recovery from intracellular pathogens, but the molecular basis of its action is still unresolved. Here, we analyzed gzmB-mediated death pathways under physiological conditions using ex vivo virus-immune CTLs that express perf and gzmB, but not gzmA (gzmB(+)CTL). We show that gzmB(+)CTL abrogate target cell proliferation most likely by inducing cell death, independent of caspases and mitochondrial signaling. In addition, the data reveal that gzmB(+)CTL independently induce pro-apoptotic processes either via caspase-3/-7, leading to plasma membrane perturbance and ROS production or via Bid/Bak/Bax, resulting in cytochrome c release and that both pathways elicit loss of DeltaPsi(m). Our data provide evidence for a pleiotropic pro-apoptotic function of gzmB presumably to counteract evasion strategies of pathogens and to control tumors.

Citing Articles

Spatial interaction and functional status of CD68SHP2 macrophages in tumor microenvironment correlate with overall survival of NSCLC.

Liu X, Zhang Z, Yuan J, Yu J, Chen D Front Immunol. 2024; 15:1396719.

PMID: 38799432 PMC: 11116570. DOI: 10.3389/fimmu.2024.1396719.


Selective Detection of Active Extracellular Granzyme A by Using a Novel Fluorescent Immunoprobe with Application to Inflammatory Diseases.

Senan-Salinas A, Comas L, Esteban P, Garzon-Tituana M, Cheng Z, Santiago L ACS Pharmacol Transl Sci. 2024; 7(5):1474-1484.

PMID: 38751645 PMC: 11092195. DOI: 10.1021/acsptsci.4c00065.


Granzyme serine proteases in inflammation and rheumatic diseases.

Aubert A, Jung K, Hiroyasu S, Pardo J, Granville D Nat Rev Rheumatol. 2024; 20(6):361-376.

PMID: 38689140 DOI: 10.1038/s41584-024-01109-5.


Granzymes in health and diseases: the good, the bad and the ugly.

Cigalotto L, Martinvalet D Front Immunol. 2024; 15():1371743.

PMID: 38646541 PMC: 11026543. DOI: 10.3389/fimmu.2024.1371743.


Hyperthermia in Combination with Emerging Targeted and Immunotherapies as a New Approach in Cancer Treatment.

Logghe T, van Zwol E, Immordino B, Van den Cruys K, Peeters M, Giovannetti E Cancers (Basel). 2024; 16(3).

PMID: 38339258 PMC: 10854776. DOI: 10.3390/cancers16030505.